Compounded Semaglutide FDA Status 2026: What's Actually Legal

If you've been following the compounded semaglutide story over the past year, it can feel like whiplash. The FDA shortage list. The removal. The legal challenges. The court injunctions. The reprieve. The new deadlines.

Here's a clear-eyed explanation of where things actually stand and what it means for patients.

Background: Why Compounded Semaglutide Existed

Compounding pharmacies are legally permitted to produce copies of FDA-approved drugs under specific conditions — most importantly, when the branded drug is in shortage. During a shortage, compounders can produce essentially identical copies at lower cost, filling the supply gap.

When Ozempic and Wegovy demand exploded post-2022, supply couldn't keep up. The FDA listed semaglutide products on its Drug Shortage Database. This opened the door for compounding pharmacies to produce semaglutide at scale — and for telehealth companies to prescribe and distribute it at a fraction of branded prices.

At peak, millions of Americans were accessing compounded semaglutide through telehealth platforms at $100-300/month versus $900-1,300/month for branded Wegovy.

The FDA's Shortage Removal and What Followed

In February 2025, the FDA removed semaglutide from its drug shortage database, effectively declaring the shortage resolved. Under federal law, this should have triggered the end of compounding — pharmacies typically have a 60-90 day wind-down period after shortage resolution before they must stop producing.

Two things happened:

Compounding pharmacy associations challenged the FDA's conclusion. The Alliance for Compounding Pharmacy and others argued that shortage conditions still existed for specific formulations and doses, and that demand continued to vastly exceed branded supply. Several legal challenges were filed.

Courts intervened. A federal district court issued a preliminary injunction halting enforcement of the shortage removal ruling while litigation proceeded. This kept compounded semaglutide legal during the legal process.

The Current Legal Status (2026)

The legal landscape as of early 2026 is complex and actively evolving:

503A pharmacies (traditional compounding for individual prescriptions) have had more protection. The legal cases primarily focused on 503B outsourcing facilities (large-scale compounders). Individual compounding for specific patients has remained on stronger legal footing throughout.

503B outsourcing facilities (large-scale compounders supplying telehealth companies) faced enforcement deadlines, injunctions, appeals, and ongoing litigation. The situation remained in legal limbo through early 2026 with multiple jurisdictions reaching different conclusions.

State-level variation is significant. Compounding pharmacy law involves both federal and state regulation. Some states have more permissive compounding frameworks; some have additional restrictions. Where your pharmacy is located and licensed matters.

The practical effect for patients: Compounded semaglutide has remained accessible through most telehealth providers throughout this period, either under ongoing legal protection or through pharmacies operating under continued injunctions. Complete enforcement has not occurred as of early 2026.

What This Means for Your Prescription

If you're currently on compounded semaglutide from a reputable telehealth provider:

Your medication is prescribed and dispensed under physician oversight. This has been the consistent baseline throughout the regulatory shifts. Individual prescriptions from licensed physicians through legitimate compounding pharmacies have faced the least regulatory pressure.

The pharmacy matters significantly. PCAB-accredited or FDA-registered 503A pharmacies operating under proper physician oversight represent the most compliant pathway. Cut-rate operations running gray-market supply chains are a different situation entirely.

The supply has continued. Despite headlines about shutdown dates and enforcement, patients receiving compounded semaglutide through established telehealth platforms have seen minimal supply disruption.

Pricing has shifted somewhat. Increased compliance costs and regulatory uncertainty have pushed compounded semaglutide prices modestly higher than peak-shortage pricing, but still far below branded alternatives.

What Tirzepatide's Status Means

Tirzepatide (Mounjaro/Zepbound) remained on the FDA's drug shortage list into 2025, which kept compounded tirzepatide in clearer legal territory than semaglutide. Brands were removed at different times and faced different legal timelines. As of early 2026, compounded tirzepatide was in a somewhat more protected position than semaglutide, though still subject to ongoing regulatory development.

For patients considering which medication to start, this regulatory status has been a practical consideration for supply continuity.

The Branded Medication Option

Branded Wegovy and Ozempic remain available — with supply now more stable than during peak shortage years — but at substantially higher cost ($900-1,300/month) and requiring manufacturer savings programs or insurance coverage to be affordable.

GoodRx, manufacturer coupons, and insurance coverage can significantly reduce branded costs for eligible patients. For patients with commercial insurance and obesity diagnoses, coverage for Wegovy (but often not Ozempic for weight loss) has expanded modestly.

The Bottom Line

Compounded semaglutide's legal status in 2026 reflects an ongoing tension between the FDA's drug shortage process, the compounding pharmacy industry's legal challenges, and the practical reality of patient demand that still exceeds branded supply capacity.

The pragmatic reality for patients: access through established, physician-supervised telehealth platforms using legitimate compounding pharmacies has remained available. The legal uncertainty is real but has not translated into widespread patient supply disruption.

The risk profile for patients goes up significantly when sourcing through unlicensed gray-market channels, unregulated online sources, or platforms without physician oversight. That's where regulatory risk and safety concerns converge.

At Marrow, compounded medications are dispensed only through licensed 503A pharmacies with physician oversight on every prescription. We monitor the regulatory environment and communicate changes to patients as they happen — because understanding what you're taking and why it's legal matters.